Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662115 | 0.92 | ALDH1A1 (0.36) | ALDH1A1NCEH1TSHR | |
| SCHEMBL8793789 | 0.84 | ALDH1A1 (0.42) | ALDH1A1NCEH1LMNAACHEHPGD | |
| SCHEMBL2655677 | 0.84 | ALDH1A1 (0.37) | ALDH1A1NCEH1TSHRLMNAHPGD | |
| SCHEMBL24372708 | 0.81 | ALDH1A1 (0.49) | ALDH1A1TSHRACHE | |
| SCHEMBL8762878 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAACHEHPGD | |
| SCHEMBL4922498 | 0.81 | ALDH1A1 (0.41) | ALDH1A1NCEH1ACHEHPGD | |
| SCHEMBL395733 | 0.80 | ALDH1A1 (0.48) | ALDH1A1NCEH1LMNAACHE | |
| SCHEMBL28103068 | 0.78 | ALDH1A1 (0.44) | ALDH1A1ACHEHPGD | |
| SCHEMBL11080267 | 0.77 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNAACHEHPGD | |
| SCHEMBL12158705 | 0.73 | ALDH1A1 (0.36) | ALDH1A1NCEH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| CN-101115735-B | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI | 2013-01-09 | — | — | CN | disclosed |
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| CN-1968921-B | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI | 2011-11-23 | — | — | CN | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-1856090-B1 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| CN-101115735-A | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1856090-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| CN-1968921-A | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI (US) | 2007-05-23 | — | — | CN | disclosed |
| WO-2006086488-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | ALDH1A1 3003/4885NCEH1 1956/4885TSHR 64/4885 |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | ALDH1A1 3337/4885NCEH1 2132/4885TSHR 57/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | ALDH1A1 3337/4885NCEH1 2132/4885TSHR 57/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | ALDH1A1 3337/4885NCEH1 2132/4885TSHR 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.